| [1] | Xiao Q., He S., Wang C., et al. (2025). Deep thought on the HIV cured cases: Where have we been and what lies ahead. Biomolecules 15:378. DOI:10.3390/biom15030378 |
| [2] | Gaebler C., Kor S., Allers K., et al. (2025). Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation. Nature 650:701−709. DOI:10.1038/s41586-025-09893-0 |
| [3] | Sáez-Cirión A., Mamez A.C., Avettand-Fenoel V., et al. (2024). Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells. Nat. Med. 30:3544−3554. DOI:10.1038/s41591-024-03277-z |
| [4] | Salgado M., Gálvez C., Nijhuis M., et al. (2024). Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study. Lancet HIV 11:e389−e405. DOI:10.1016/s2352-3018(24)00090-0 |
| [5] | Wu H.L., Busman-Sahay K., Weber W.C., et al. (2023). Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. Immunity 56:1649−1663.e1645. DOI:10.1016/j.immuni.2023.04.019 |
| Xiao Q., Xiang H., Shu X., et al. (2027). Beyond CCR5Δ32 homozygosity: The second Berlin Patient reveals crucial immune-mediated pathways to HIV cure. The Innovation Medicine 5:100276. https://doi.org/10.59717/j.xinn-med.2027.100276 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
The lessons learned from the second Berlin (B2) patient and the future research directions in HIV cure